Gene · 64761
Papers1,639
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,639
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy. | DNA Repair (Amst) | 2025 | 40203475 | PubTator, text mining | PubMed |
| 1H, 13C and 15N chemical shift assignments of Rubella virus macro domain in the free and in the ADPr bound state. | Biomol NMR Assign | 2025 | 40186845 | PubTator, text mining | PubMed |
| A structure-based framework for selective inhibitor design and optimization. | Commun Biol | 2025 | 40075154 | PubTator, text mining | PubMed |
| Duplexed CeTEAM drug biosensors reveal determinants of PARP inhibitor selectivity in cells. | J Biol Chem | 2025 | 40021124 | PubTator, text mining | PubMed |
| Targeting the DNA damage response through TBL1X in mantle cell lymphoma. | Blood Adv | 2025 | 40009753 | PubTator, text mining | PubMed |
| First-In-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors. | Cancer Med | 2025 | 39945311 | PubTator, text mining | PubMed |
| Zinc-finger PARP proteins ADP-ribosylate alphaviral proteins and are required for interferon-γ-mediated antiviral immunity. | Sci Adv | 2025 | 39888989 | Swiss-Prot, curated | PubMed |
| Replication-Poison Treatment in BRCA1-Deficient Breast Cancer Causes MRE11 Over-Resection That Induces Single-Stranded DNA Accumulation and Mitotic Catastrophe. | Cancer Res | 2025 | 39879120 | PubTator, text mining | PubMed |
| CHD6 has poly(ADP-ribose)- and DNA-binding domains and regulates PARP1/2-trapping inhibitor sensitivity via abasic site repair. | Nat Commun | 2025 | 39863586 | PubTator, text mining | PubMed |
| PARP12-mediated ADP-ribosylation contributes to breast cancer cell fate by regulating AKT activation and DNA-damage response. | Cell Mol Life Sci | 2025 | 39847113 | PubTator, text mining | PubMed |
| Screening and design of PARP12 inhibitors from traditional Chinese medicine small molecules using computational modeling and simulation. | J Biomol Struct Dyn | 2025 | 39527026 | PubTator, text mining | PubMed |
| The Discovery of a Potent PARP1 Inhibitor Senaparib. | Mol Cancer Ther | 2025 | 38920409 | PubTator, text mining | PubMed |
| Evaluation of the efficacy of marine natural products against PARP-1/2 proteins in high-grade serous ovarian cancer: insights into MD and SMD simulations. | J Biomol Struct Dyn | 2025 | 38887043 | PubTator, text mining | PubMed |
| Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM. | Nat Commun | 2024 | 39643609 | PubTator, text mining | PubMed |
| Viral RNA Interactome: The Ultimate Researcher's Guide to RNA-Protein Interactions. | Viruses | 2024 | 39599817 | PubTator, text mining | PubMed |
| Leveraging homologous recombination deficiency for sarcoma : Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. | Pathologie (Heidelb) | 2024 | 39535612 | PubTator, text mining | PubMed |
| PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives. | Cancer Treat Rev | 2024 | 39531943 | PubTator, text mining | PubMed |
| IRF1-mediated upregulation of PARP12 promotes cartilage degradation by inhibiting PINK1/Parkin dependent mitophagy through ISG15 attenuating ubiquitylation and SUMOylation of MFN1/2. | Bone Res | 2024 | 39465252 | Swiss-Prot, curated | PubMed |
| Side effect management algorithms for niraparib/abiraterone acetate in prostate cancer. | Can J Urol | 2024 | 39462528 | PubTator, text mining | PubMed |
| H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. | bioRxiv | 2024 | 39253432 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64761/papers?page=5